-
Posted by
Two Blokes Tue at 1:15 PM -
Filed in
Stock
-
0 views
Vertex Pharmaceuticals missed Q1 revenue and EPS estimates but this is not a cause for concern as the full-year outlook has improved. Alyftrek is off to a good start and early launch metrics of Journavx look promising. Casgevy's progress is slow but uptake should improve going forward.
